Table 3. Proportion of subjects with 4-fold increase from baseline in anti-EBA175 antibody response.

Study Day	Treatment Group	Number Tested	Number of Responders	95% CI for Responders
Day 14	5 μg EBA-175	18	1 (5.6)	[0.1, 27.3]
	20 μg EBA-175	18	5 (27.8)	[9.7, 53.5]
	80 μg EBA-175	18	5 (27.8)	[9.7, 53.5]
	Placebo	6	1 (16.7)	[0.4, 64.1]
Day 28	5 μg EBA-175	18	3 (16.7)	[3.6, 41.4]
	20 μg EBA-175	18	10 (55.6)	[30.8, 78.5]
	80 μg EBA-175	18	7 (38.9)	[17.3, 64.3]
	Placebo	6	1 (16.7)	[0.4, 64.1]
Day 42	5 μg EBA-175	17	9 (52.9)	[27.8, 77.0]
	20 μg EBA-175	18	13 (72.2)	[46.5, 90.3]
	80 μg EBA-175	18	13 (72.2)	[46.5, 90.3]
	Placebo	5	0 (0)	[0, 0]
Day 180	5 μg EBA-175	16	5 (31.3)	[11.0, 58.7]
	20 μg EBA-175	18	14 (77.8)	[52.4, 93.6]
	80 μg EBA-175	18	11 (61.1)	[35.7, 82.7]
	Placebo	5	0 (0)	[0, 0]
Day 194	5 μg EBA-175	16	10 (62.5)	[35.4, 84.8]
	20 μg EBA-175	18	13 (72.2)	[46.5, 90.3]
	80 μg EBA-175	18	16 (88.9)	[65.3, 98.6]
	Placebo	3	0 (0)	[0, 0]

Vaccinations occurred on Days 0, 28 and 180. Blood samples were drawn for immunogenicity prior to vaccination.